Mar 28, 2019 Cardiotool Novità Fibrillazione Atriale Commenti disabilitati su Atrial fibrillation and concomitant heart failure with preserved, mid-range, and reduced ejection fraction: results of the Russian observational survey
TERESHCHENKO S.N., ZHIROVI.V., SAFRONOVA N.V., OSMOLOVSKAYA Yu.F.
National medical research center of cardiology of the Ministry of healthcare of the Russian Federation, 121552, Moscow, 3rd Cherepkovskaya St., house 15A
Background: Heart failure (HF) and atrial fibrillation (AF) are the most common cardiovascular conditions in clinical practice and frequently coexist. There is a gap in understanding of the clinical pattern of HF and AF comorbidity and in selection of the optimal treatment strategies. Aim: To evaluate clinical outcomes of patients with atrial fibrillation and concomitant heart failure with preserved, mid-range, and reduced ejection fraction at 12-month follow-up.
Methods: In multicenter prospective observational study was recruited 1003 patients with heart failure and atrial fibrillation between February 2015 and January 2016. Patients were enrolled to participate in the survey at 30 medical centers in 21 provinces of the Russian Federation and followed up at 12 months. All patients had ECG-documented diagnosis of atrial fibrillation and heart failure with preserved (AF-HFpEF), mid-range (AF-HFmrEF) or reduced (AF-HFrEF) ejection fraction. Patients with ejection fraction ≥40% were eligible for study if they had level of BNP or NT-proBNP larger then100 pg/ml or 300 pg/ml, respectively.
Results: Almost half of patients (46.5%) had AF-HFrEF; 38.6 and 15% of patients had AF-HFpEF and AF-HFmrEF ejection fractions, respectively. Patients with preserved ejection fraction were significantly older and more often women. During the one-year follow-up, 574 (57.2%) patients were hospitalized due to worsening heart failure at least once. The most frequency of HF hospitalization was observed in the AF-HFmrEF group (66%). AF-HFrEF associated with significantly higher cardiovascular mortality rate, 4.1, 9.3 and 15.5% in the AF-HFpEF, AF-HFmrEF, and AF-HFrEF groups, respectively (p<0.001). The rate of all thromboembolic events in the total cohort was 3.4%; the rate of ischemic stroke was 2.7%. The groups were comparable in the rate of thromboembolic events (p=0.451).
Conclusions: Our data shows that reduced ejection fraction increases the risk of cardiovascular mortality but not the risk of thromboembolic events (such as stroke and systemic embolism).
Trial registration: NCT02790801
Questo contenuto è riservato agli utenti registrati appartenenti al settore sanitario: si prega di accedere utilizzando il form sottostante, oppure di compilare il form di registrazione. Dopo la registrazione, oltre ad avere accesso a tutti i contenuti del portale, riceverai aggiornamenti utili alla pratica clinica. Se non si ricordano i dati di accesso, cliccare qui
Nov 07, 2020 Commenti disabilitati su Pneumopatia da COVID-19: il punto di vista del Medico Vascolare. “Position paper” patrocinato dalla SIDV e della SIMV
Ott 12, 2020 Commenti disabilitati su Scompenso cardiaco con frazione di eiezione conservata: 5 cose da sapere
Ott 12, 2020 Commenti disabilitati su Pazienti con diabete tipo 2 a maggior rischio di demenza vascolare rispetto ad altre demenze
Feb 17, 2020 Commenti disabilitati su Sanguinamento gastrointestinale e rischio di carcinoma del colon-retto in pazienti anticoagulati con fibrillazione atriale
Gen 28, 2020 Commenti disabilitati su La fibrillazione atriale può essere un segno di aldosteronismo primario nei pazienti con ipertensione
Gen 05, 2020 Commenti disabilitati su Il Cuore Che Verrà